Zonalon

Insomnia, Neurotic depression, Depression + 8 more
Treatment
20 Active Studies for Zonalon

What is Zonalon

DoxepinThe Generic name of this drug
Treatment SummaryDoxepin is a medication used to treat depression and anxiety. It works by blocking certain receptors in the brain that are linked to these conditions. Doxepin is a type of antidepressant known as a tricyclic, which means it shares properties with other drugs in its class like amitriptyline and desipramine. It was first developed by Pfizer and approved by the FDA in 1969 as an antidepressant. In 2010, it was also approved to treat insomnia.
Sinequanis the brand name
image of different drug pills on a surface
Zonalon Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Sinequan
Doxepin
1969
307

Effectiveness

How Zonalon Affects PatientsDoxepin is a type of antidepressant that works by decreasing the electrical activity of the brain. It can have effects such as making someone feel calmer and easing depression, but it can also make them feel sleepy. These effects usually take a few weeks to be fully felt, but the sedative effect is felt right away. High doses produce more noticeable side effects, like dizziness, confusion, and dry mouth.
How Zonalon works in the bodyDoxepin works by blocking histamine receptors, which helps relieve skin conditions. It also works on the central nervous system to increase levels of norepinephrine and serotonin at synapse nerve terminals. This helps increase activity at post-synaptic neuron receptor sites and desensitizes serotonin 1A receptors and beta-adrenergic receptors. Finally, it increases dopamine levels in the frontal cortex, which helps improve its transmission in this area.

When to interrupt dosage

The prescribed measure of Zonalon depends on the recognized condition, including Depression, Involutional, Mental Disorder, Organic and Insomnia. The magnitude of dosage is contingent upon the method of delivery (e.g. Oral or Tablet - Oral) featured in the below table.
Condition
Dosage
Administration
Insomnia
, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %
, Oral, Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated
Neurotic depression
, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %
, Oral, Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated
Depression
, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %
, Oral, Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated
Generalized Anxiety Disorder
, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %
, Oral, Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated
Neuropathic Pain
, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %
, Oral, Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated
Itching
, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %
, Oral, Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated
Depressive Disorder, Major
, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %
, Oral, Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated
Behcet Syndrome
, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %
, Oral, Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated
Alcoholism
, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %
, Oral, Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated
Depressive Disorder, Major
, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %
, Oral, Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated
Neurodermatitis
, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %
, Oral, Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated - Oral, Tablet, film coated

Warnings

Zonalon has four potential contraindications and should not be utilized when any of the conditions specified in the following table are present.Zonalon Contraindications
Condition
Risk Level
Notes
untreated narrow angle glaucoma
Do Not Combine
Pulse Frequency
Do Not Combine
Urinary Retention
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Doxepin may interact with Pulse Frequency
There are 20 known major drug interactions with Zonalon.
Common Zonalon Drug Interactions
Drug Name
Risk Level
Description
4-Methoxyamphetamine
Major
Doxepin may increase the vasopressor activities of 4-Methoxyamphetamine.
Acepromazine
Major
Doxepin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.
Aclidinium
Major
The risk or severity of adverse effects can be increased when Doxepin is combined with Aclidinium.
Alfuzosin
Major
Doxepin may increase the hypotensive activities of Alfuzosin.
Aripiprazole
Major
Doxepin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole.
Zonalon Toxicity & Overdose RiskTaking too much doxepin can cause seizures, abnormal heart rhythms, coma, low blood pressure, or even death. It has also been linked to reduced fertility in both males and females, including reduced number of viable embryos and lower sperm motility. There is no evidence to suggest that doxepin is carcinogenic or mutagenic.
image of a doctor in a lab doing drug, clinical research

Zonalon Novel Uses: Which Conditions Have a Clinical Trial Featuring Zonalon?

A vast 1020 active trials are being conducted to explore the potential of Zonalon in providing relief from Generalized Anxiety Disorder, Atopic Dermatitis and Bipolar Disorder.
Condition
Clinical Trials
Trial Phases
Generalized Anxiety Disorder
178 Actively Recruiting
Not Applicable, Phase 2, Early Phase 1, Phase 4, Phase 1, Phase 3
Depressive Disorder, Major
0 Actively Recruiting
Insomnia
0 Actively Recruiting
Depression
300 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3
Alcoholism
7 Actively Recruiting
Not Applicable, Phase 2, Phase 3
Neurotic depression
0 Actively Recruiting
Depressive Disorder, Major
0 Actively Recruiting
Itching
2 Actively Recruiting
Phase 3, Not Applicable
Behcet Syndrome
1 Actively Recruiting
Not Applicable
Neuropathic Pain
4 Actively Recruiting
Not Applicable, Phase 1, Phase 2
Neurodermatitis
0 Actively Recruiting

Zonalon Reviews: What are patients saying about Zonalon?

5Patient Review
11/30/2013
Zonalon for Itching
Over-the-counter itch creams and cold compresses failed to provide me with any relief from my neurodermatitis. This prescription, however, was very effective. I got instant relief but it made me drowsy.
5Patient Review
9/7/2009
Zonalon for Skin Rash that Becomes Thick & Discolored From Rubbing It
Shoulder and hip pain has been a problem for me for a while, but after using this treatment, I get quick and long-lasting relief. I highly recommend it to anyone with similar issues.
4.7Patient Review
2/1/2014
Zonalon for Skin Rash that Becomes Thick & Discolored From Rubbing It
Worked great for my severe pain from shingles, but I unfortunately developed an allergy to it. Now I'm on the lookout for a new treatment that can help me with the pain in my left armpit.
3Patient Review
6/6/2010
Zonalon for Itching
The itching on my forearms has decreased with use, but now the skin is more red. I'll keep using it for now, but I'm also going to look for other options.
1Patient Review
12/19/2008
Zonalon for Skin Rash that Becomes Thick & Discolored From Rubbing It
I've tried this medication for three weeks now and I haven't seen any results. In fact, I think I'm having an allergic reaction to it. My eyes are itching, my genitals are rashy, and I feel itchy all over.
1Patient Review
9/17/2009
Zonalon for Itching
I don't think this would be effective for shingles.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about zonalon

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is doxepin and what are the side effects?

"Doxepin is a medication used to treat depression and anxiety by increasing the levels of certain natural substances in the brain. It is also available in tablet form to treat insomnia."

Answered by AI

Who makes Zonalon?

"Doxepin hydrochloride (equivalent to 4.4% doxepin) in a vehicle of sorbitol, cetyl alcohol, isopropyl myristate, glyceryl stearate, PEG-100 stearate, petrolatum, benzyl alcohol, titanium dioxide and purified water."

Answered by AI

What is the drug doxepin used for?

"Doxepin is a medication used to treat symptoms of anxiety or depression, as well as insomnia. It is classified as a tricyclic antidepressant (TCA), meaning it works by affecting the levels of certain chemicals in the brain."

Answered by AI

What is Zonalon cream used for?

"This medication is used to relieve itchiness from certain skin conditions such as eczema, neurodermatitis, and atopic dermatitis. However, it should only be used for a short amount of time not exceeding 8 days."

Answered by AI

Clinical Trials for Zonalon

Image of Cedars-Sinai Medical Center in Los Angeles, United States.

Living Well Program for Anxiety in Breast Cancer

18+
Female
Los Angeles, CA
The goal of this study is to evaluate the efficacy and cost-effectiveness of the Living Well Program, a digital therapeutic application with telecoaching support, in breast cancer patients with moderate-to-severe anxiety. The main question the study aims to answer is: does digital cognitive-behavioral therapy-based interventions decrease the overall healthcare costs of patients with stage II to IV breast cancer? The study has one group of participants who will use the Living Well app and telecoaching support. This group will be compared to retroactively matched controls. Over 3 months, patients will complete 21 mental health modules and 5 telecoaching sessions. In the following 3 months, they will complete any outstanding telecoaching sessions and modules while still being monitored, even if they finished all modules and sessions in the first 3 months. The 6 months after that will be the follow-up phase. They will still have access to the Living Well app and may continue to use it, and they will complete the same assessment questionnaires as baseline to identify any changes in their overall mental health.
Waitlist Available
Has No Placebo
Cedars-Sinai Medical CenterScott Irwin, MD
Image of University of California San Diego in La Jolla, United States.

AI Chatbot for Postpartum Loneliness

18+
Female
La Jolla, CA
The goal of this clinical trial is to learn whether a postpartum chatbot powered by generative artificial intelligence (genAI) can help new mothers get better pelvic floor health information and feel less lonely after childbirth. The main questions this study aims to answer are: * Does using the chatbot improve postpartum pelvic floor health knowledge? * Does using the chatbot help reduce feelings of loneliness during the postpartum period? * Does using the chatbot impact pelvic floor symptoms? Researchers will compare standard postpartum care to standard care plus the chatbot. Participants will: Be assigned by chance (like flipping a coin) to standard postpartum care with or without access to the chatbot. If in the chatbot group, participants will receive education and support via the chatbot over a 4-week period. Both groups will complete questionnaires to measure their pelvic floor knowledge, pelvic floor symptoms, feelings of loneliness, depression, infant bonding, perceived social support, adverse childhood experiences, and peri-traumatic distress. The chatbot was created by urogynecology experts in collaboration with UC San Diego computer science and biomedical informatics researchers. The chatbot is designed to give new mothers personalized, evidence-based information and support in real time.
Waitlist Available
Has No Placebo
University of California San Diego
Have you considered Zonalon clinical trials? We made a collection of clinical trials featuring Zonalon, we think they might fit your search criteria.Go to Trials
Image of Mayo Clinic in Florida in Jacksonville, United States.

Virtual Reality for Cancer

18 - 90
All Sexes
Jacksonville, FL
This clinical trial tests the safety, tolerability, and effectiveness of a virtual reality intervention to improve psychological symptom burden for cancer patients undergoing treatment. Virtual reality (VR) is a technology that allows users to experience and interact with three-dimensional, computer-generated environments that simulate the real world or imagined settings. The VR intervention consists of a preloaded with immersive environments designed to engage the senses through simulated sights and sounds. This may include a walk through of a serene forest, exploring vibrant coral reefs, swimming with dolphins, or standing at the base of a majestic waterfall. These environments are created to provide a relaxing and engaging experience. Completing the VR intervention may be a safe and effective way to improve quality of life, reduce anxiety, enhance focus, and promote healthy living for cancer patients undergoing treatment.
Recruiting
Has No Placebo
Mayo Clinic in FloridaJuan C. Cardenas Rosales, MD
Image of Virtual/ No Physical Facility in Palm City, United States.

Akashic Records Sessions for Mental Health

18+
All Sexes
Palm City, FL
The goal of this clinical study is to learn the impact of two Akashic Records sessions on mental health symptoms in adults. We want to see how sessions are linked to stress, anxiety, and depression, and to resilience (ability to bounce back) and feelings of connectedness (to self, community, and humanity). Main questions this study will answer are: After two sessions, what is the impact on stress, anxiety, and depression? After two sessions, what is the impact on resilience and connectedness? How do participants describe their experience of the sessions? After two sessions, what are participants' views of their problems (insight), emotional experiences (impact) and observable behaviors in their daily life? What participants will do: Complete online surveys about their mood at four points: before the first session, before the second session, after the second session, and again 2 months later. Surveys include: DASS-21 (Depression, Anxiety, and Stress Scale) CD-RISC-10 (Connor-Davidson Resilience Scale) WATTS (Connectedness Scale) A short demographic form and satisfaction survey Attend two individual Akashic Records sessions (50-90 minutes each) over private video platform with a licensed clinical social worker (principal investigator) The first 50 participants will also join a one-hour interview with open ended questions with a licensed clinical social worker (co-investigator) about one week after the second session to share their experience in their own words. Who can take part: Adults ages 18 and older who can read and consent in English and who have experienced stress, anxiety, or low mood in the past year. How the research will happen: Sessions are held by secure video call. Participants will also complete private online surveys before, during, and after the sessions. Some participants may be invited to share their experiences in a one-on-one interview. All information is kept private and names are removed before analysis. Risks and benefits: Talking about personal topics may bring up strong emotions. Licensed clinicians conduct sessions, offer support, and provide referrals if needed. Possible benefits include new insights, greater peace or meaning, and improved coping; benefits are not guaranteed. Why this matters: Many people seek spiritual or transpersonal support for emotional concerns. This pilot study will provide early evidence on whether Akashic Records sessions may be a helpful, low-risk option and will guide future research.
Waitlist Available
Has No Placebo
Virtual/ No Physical FacilityCandice S Rasa, LCSW
Image of University of California, Los Angeles in Los Angeles, United States.

Virtual Reality Reward Training for Depression

18+
All Sexes
Los Angeles, CA
The purpose of this study is to compare the effects of enhanced Virtual Reality-Reward Training (eVR-RT) with an active control condition, Virtual Reality-Memory Training (VR-MT), on positive affect and other clinical symptoms. Enhanced VR-Reward Training is a novel intervention aimed at enhancing savoring of positive experiences among individuals with depression and low positive affect through guided imaginal recounting following immersion in positive VR experiences. The current study tests an enhanced version of this training using improved virtual reality technology. Target enrollment is 80 participants with low positive affect, depression, and impaired functioning, who are at least 18 years old, who will be randomly assigned to 7 weeks of either enhanced Virtual Reality-Reward Training (VR-RT) or Virtual Reality-Memory Training (VR-MT). Participants will complete in-person VR sessions, laboratory assessments, self-report questionnaires as part of the study. A subset of 8 participants randomly assigned to VR-RT will complete fMRI scans and EMA surveys. The total length of participation is around 3 months.
Phase 2
Recruiting
University of California, Los Angeles
Have you considered Zonalon clinical trials? We made a collection of clinical trials featuring Zonalon, we think they might fit your search criteria.Go to Trials
Image of Caron Treatment Centers in Wernersville, United States.

Safe and Sound Protocol for Substance Abuse

18 - 75
All Sexes
Wernersville, PA
This study will explore whether the use of the Safe and Sound Protocol (SSP) app is an effective adjunct to treatment as usual (TAU) in individuals with co-occurring substance use disorders and trauma. This study will recruit 129 participants (100 completers) randomized to receive either active or sham SSP in addition to TAU. Participants will utilize the SSP for a minimum of three hours to a maximum of five hours for a total of seven days. Data will be collected at both pre- and post-test. Data to be collected will include measures on affect, anxiety, personality, mindfulness, and posttraumatic stress disorder symptoms. The SSP has shown effectiveness in reducing symptoms of anxiety, depression, and trauma symptoms in pilot studies conducted at other locations. This will be the first study to examine the effectiveness of SSP with individuals with co-occurring SUD and trauma.
Waitlist Available
Device
Caron Treatment CentersErin Deneke, PhD
Image of Cresap Laboratory in Evanston, United States.

Dream Yoga Inspired Intervention for Anxiety

18+
All Sexes
Evanston, IL
This is a feasibility study to test whether it is possible to deliver a program inspired by Tibetan Dream Yoga in a modern, accessible way. Dream Yoga is a set of contemplative practices that combine mental exercises during the day with techniques for becoming aware of dreaming within a dream (lucid dreaming) and engage in certain dream activities. The purpose of these practices is to help people explore and loosen rigid patterns of thought and behavior. In this study, the investigators are developing and testing a program that includes guided imagination, meditation, and lucid-dreaming practices, supported by virtual-reality experiences and home-based sleep-monitoring technology. Participants are randomly assigned to either the Dream-Yoga-inspired program or a comparison program focused on general health and sleep education. Because this is a feasibility trial, our main goals are to see whether people are willing and able to take part, whether they find the program acceptable, and whether the investigators can deliver it as planned. The investigators will also explore early signals of change in sleep, dreaming, and thinking. The long-term goal of this research is to determine if such interventions could be beneficial for supporting psychological well-being, improving sleep, and enhancing creativity and flexibility of thought.
Phase < 1
Waitlist Available
Cresap Laboratory (+1 Sites)
Image of Center for Technology and Behavioral Health (CTBH), Geisel School of Medicine at Dartmouth College in Lebanon, United States.

Advertising Claims for Anxiety and Depression

18+
All Sexes
Lebanon, NH
In the U.S., legal cannabis is frequently advertised as an effective treatment for mental health problems such as anxiety and depression-particularly online. States that have legalized cannabis have not implemented regulations to address this type of advertising. This project aims to investigate the influence of psychotherapeutic advertising claims (PAC) and mental health warning labels (WL) on online cannabis purchasing behaviors among light-to-moderate cannabis users with symptoms of depression and/or anxiety. The specific aims are to determine whether PAC increases cannabis purchasing intentions and whether a mental health WL can mitigate this effect. A realistic online cannabis shopping experience will be simulated using the digital Platform for Online Evaluation of Marijuana Marketing and Sales (POEMMS). The study will employ a between-subjects experimental design by randomizing 2,000 participants to one of four online stores that vary in PAC and WL content: (1) a control claims (CC)-only store, (2) a PAC store, (3) a WL store, and (4) a PAC + WL store. Participants will browse and select items as if making real purchases. Analyses will examine three primary outcomes to determine the influence of PAC and WL on purchasing behaviors: (1) total milligrams of THC purchased, (2) average potency (%THC) of products, and (3) overall number of products purchased. The long-term objective is to inform evidence-based cannabis policy and regulatory strategies by understanding the impact of cannabis marketing on vulnerable populations. This research is relevant to public health by addressing the potential risks associated with misleading cannabis marketing, which may lead to increased use and exacerbation of mental health symptoms among individuals with depression and anxiety. The project leverages a multidisciplinary team with expertise in addiction, mental health, epidemiology, and digital health technology. The findings have the potential to inform the development of targeted interventions and policies to reduce harms associated with cannabis advertising-ultimately contributing to better health outcomes and more effective regulation.
Waitlist Available
Has No Placebo
Center for Technology and Behavioral Health (CTBH), Geisel School of Medicine at Dartmouth CollegeJennifer Emond, PHD
Have you considered Zonalon clinical trials? We made a collection of clinical trials featuring Zonalon, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security